Today, an increasing number of Americans across the political spectrum, from Make America Healthy Again activists to everyday shoppers, are voicing concern about the health impact of ultrarocessed foods, those boxed and wrapped in plastic, ready to eat items lining grocery store shelves. Leading the charge are two men who disagree on pretty much everything else about public health. Health and Human Services Secretary Robert F.Kennedy Jr. . and Dr. . David Kesler, the former commissioner of the US Food and D ...

Obesity and infertility treatments are among the first crop to appear with discounts on the government-run platform. https://t.co/LSGe7FoDZZ ...

Hello everyone. A few days back I had a 14-year-old child who came holding his mother's hand to my OPD. He was obese but otherwise looked quite bright, comfortable. But when I saw his reports, I was shocked. My heart sank. The reports were suggestive of type 2 diabetes malitis. And the mother told me, "Sir, there's no problem I see in him ex and he doesn't eat much food. He just takes chips, biscuits, cold drinks, and noodles. What most of the kids and adolescents like these days mind the words what most of ...

When you look at our food system today, majority of what people are eating is ultrarocessed crap. The average child spends less time outside than like a maximum security prison where people are spending eight plus hours on phone. We are in the midst of one of the biggest problems in the country.If we don't fix this, like America is going to have even more serious problems. The environment that we exist in is just structurally just hard to be healthy, which is why you see the default health outcomes in the U ...

Obesity in Chinese cats is widespread. Now one drugmaker is seeking approval for a feline weight-loss drug. https://t.co/qkhjYxKQKl ...

كلنا بنستنى يوم السبت علشان نبدا في البايت بتاعنا او نستنى اول الشهر علشان يبدا مرهص الدايت ما ينفعش دايت يبدا في نص الاسبوع ابدا نفتح شطيب او نفتح كالوري اي هنطلع بلان هنمشي عليها اسبوعين شهر ثلاث شهور وبعد كده النت جاي هتخس شويه وبعدين اول ما توقفها هيزيد وزنك كله تاني لو جينا هنا نتكلم عن اول حاجه وتصنع كلمه دايب هو ممنوع العيش ممنوع الرز ممنوع المكرونه طب البيض كفايه بيضه واحده قوي في الاسبوع اصله بيعلي الكوليسترول حاجه كمان فوم اكتر من 18 ساعه وكل وجبه واحده في اليوم هي دي الحاجه الوحيده اللي ممكن تخسس ...

The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars. https://t.co/ZK1T7NTEfV ...

Novo Nordis's chairman said the Danish drugmaker must protect its obesity business from being eroded with falling prices, as the industry pioneer squares off against rapidly strengthening rivals. https://t.co/yrkiP8RwDT ...

[music] [music] [music] You've been waiting. [music] You been waiting. >> [music] [music] [music] >> Heat. Heat. [music] >> [music] [music] [music] [music] >> Heat.Heat. Heat. Heat. Heat. [music] [music] >> [music] [music] >> Heat.>> [music] >> So without further ado, let's begin this enthralling journey with our first speaker of the day, Miss Sinisha. Soisha is a revered RDN certified by the Academy of Nutrition and Dietetics. She holds a degree in food sciences and human nutrition specializing in dietetic ...

Lexicon Pharmaceuticals FY Conference Summary Company Overview - **Company**: Lexicon Pharmaceuticals (NasdaqGS:LXRX) - **Event**: 44th Annual JPMorgan Healthcare Conference - **Date**: January 15, 2026 Key Points Industry and Company Background - Lexicon Pharmaceuticals was founded 30 years ago with a focus on gene research, creating knockout mouse lines for 5,000 genes, identifying 200 genes of interest [2][3] - The company has conducted over 80 clinical trials, resulting in the approval of two medicines in the U.S., including INPEFA for heart failure and a novel approach for neuropathic pain [3][4] Product Pipeline and Therapeutic Areas - **Cardiometabolic Disease**: - INPEFA has been commercialized in the U.S. and is in phase three trials for hypertrophic cardiomyopathy (HCM) [5][9] - Zynquista is under regulatory discussions for type 1 diabetes [5][9] - LX9851 is a first-in-class non-incretin mechanism for obesity, currently licensed to Novo Nordisk [5][19] - **Pain Management**: - Pivapladin is a first-in-class AAK1 inhibitor for neuropathic pain, entering phase three trials in 2026 [6][18] - There is a significant unmet need in neuropathic pain, with approximately 9 million patients in the U.S. suffering from diabetic peripheral neuropathic pain (DPNP) [16][31] Clinical Trials and Regulatory Pathways - The SONATA trial for HCM is progressing well, with enrollment expected to conclude in the first half of 2026 [10][20] - The FDA has agreed on the parameters for resubmission of Zynquista, focusing on prospective data to assess the risk of diabetic ketoacidosis [27][28] - Pivapladin has shown significant placebo-adjusted improvements in pain scores, supporting its advancement into phase three trials [18][32] Market Opportunities - The cardiometabolic market is of high interest, particularly for HCM, which affects about 1 million people in the U.S. [11][25] - The DPNP market is characterized by a lack of effective treatments, creating a strong demand for new non-opioid options like Pivapladin [16][32] - The obesity treatment market is shifting towards oral medications, with a focus on improving tolerability and long-term adherence [33] Financial Position and Future Goals - Lexicon ended the previous year with approximately $125 million in cash, supporting operations into 2027 [20] - Goals for 2026 include advancing the late-stage pipeline, supporting partnerships with Novo Nordisk and Viatris, and maintaining financial discipline [20][36] Additional Insights - The company is focused on operational excellence and has implemented a virtual sales force for INPEFA to ensure continuous availability [8] - Legislative support for non-opioid pain treatments is growing, which may facilitate market access for Pivapladin [17][32] Conclusion Lexicon Pharmaceuticals is strategically positioned in the cardiometabolic and pain management sectors, with a robust pipeline and significant market opportunities. The company is focused on advancing its clinical trials and regulatory submissions while maintaining a strong financial position to support long-term growth.